Johnson & Johnson (NYSE:JNJ) is First Financial Bankshares Inc’s 10th Largest Position

First Financial Bankshares Inc lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.4% in the 4th quarter, Holdings Channel reports. The firm owned 645,357 shares of the company’s stock after acquiring an additional 15,291 shares during the period. Johnson & Johnson accounts for 2.0% of First Financial Bankshares Inc’s portfolio, making the stock its 10th biggest holding. First Financial Bankshares Inc’s holdings in Johnson & Johnson were worth $93,332,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Johnson & Johnson during the fourth quarter valued at $1,339,878,000. Janus Henderson Group PLC increased its position in Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after acquiring an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. increased its position in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Amundi increased its position in Johnson & Johnson by 16.2% during the fourth quarter. Amundi now owns 11,930,183 shares of the company’s stock valued at $1,698,984,000 after acquiring an additional 1,660,458 shares during the last quarter. Finally, Holocene Advisors LP purchased a new stake in Johnson & Johnson during the third quarter valued at $225,040,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.9 %

Shares of JNJ stock opened at $164.24 on Wednesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock’s 50 day simple moving average is $155.73 and its two-hundred day simple moving average is $156.25. The company has a market cap of $395.80 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the business posted $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Analyst Ratings Changes

A number of analysts recently commented on JNJ shares. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Bank of America boosted their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Leerink Partners cut their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.